Notices

- Notice of Information: Updates and clarifications of several components of the Challenge competition posted within the Federal Register (NOT-OD-19-046) National Institutes of Health

- PRE-APPLICATION PAR-19-128 BIOMEDICAL RESEARCH FACILITIES (C06) WEBINAR (NOT-OD-19-052) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- NIH Policy for Review and Resubmission of New Investigator R01 Applications (NOT-OD-19-053) Center for Scientific Review


- Notice of Clarification Regarding Harassment and Discrimination Protections in NIH Training Applications (NOT-OD-19-056) National Institutes of Health

- Extension of Comment Period on Draft Report: Reducing Administrative Burden to Researchers for Animal Care and Use in Research (NOT-OD-19-057) National Institutes of Health

- Register to Attend the NIH Regional Seminar on Program Funding and Grants Administration Baltimore, MD May 2019 (NOT-OD-19-058) National Institutes of Health

- Notice of NIAID's Participation in PAR-19-158 "Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)" (NOT-AI-19-031) National Institute of Allergy and Infectious Diseases

- Notice of Intent to Publish Funding Opportunity Announcements for Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research (R01 and U01, Clinical Trial Optional) (NOT-AI-19-032) National Institute of Allergy and Infectious Diseases

- Notice of NIAMS Participation in "Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)" (NOT-AR-19-034) National Institute of Arthritis and Musculoskeletal and Skin Diseases
• Notice of Correction to Application Form Instructions for PAR-18-829, "NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)"
  (NOT-AT-19-017)
  National Center for Complementary and Integrative Health

• Notice of Updated Application Forms Package for PAR-18-828, "NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)"
  (NOT-AT-19-018)
  National Center for Complementary and Integrative Health

• Notice of Added Receipt Dates and Later Expiration Date for PA-19-029, Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed)
  (NOT-CA-19-017)
  National Cancer Institute

• Pre-Application Webinar for RFA-CA-19-033, Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)
  (NOT-CA-19-020)
  National Cancer Institute

• Notice of Correction to Award Budget for PA-18-916 AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
  (NOT-DA-19-011)
  National Institute on Drug Abuse

• Request for Information (RFI): Inviting Comments on the NIDA Strategic plan for Research at the Intersection of HIV/AIDS and Substance Use, Misuse and Addiction
  (NOT-DA-19-015)
  National Institute on Drug Abuse

• Notice of Pre-Application Information Webinar and Frequently Asked Questions (FAQs) for HEAL Initiatives RFA-DA-19-035 (UG3/UH3) and RFA-DA-19-034 (U24): Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) Initiative "
  (NOT-DA-19-017)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Alcohol Abuse and Alcoholism

• Notice of Expiration for PA-18-627 NIDA Academic Research Enhancement Award (R15 Clinical Trial Required)
  (NOT-DA-19-018)
  National Institute on Drug Abuse

• Notice to Expire PA-18-343 'Academic Research Enhancement Award (R15 Clinical Trial Required)'
  (NOT-DC-19-004)
  National Institute on Deafness and Other Communication Disorders
- Notice of NIDCR Participation in RFA-DA-19-035 "HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) (UG3/UH3 Clinical Trial Required)"
  (NOT-DE-19-001)
  National Institute of Dental and Craniofacial Research

- Notice of Pre-Application Webinar for RFA-DE-19-007 "NIDCR Mentoring Network to Support a Diverse Dental, Oral and Craniofacial Research Workforce (UE5 Clinical Trial Not Allowed)"
  (NOT-DE-19-002)
  National Institute of Dental and Craniofacial Research

- Notice of Special Interest in Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development
  (NOT-DK-19-007)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Science Research

- Notice to Extend the Expiration Date for PAR-18-102: Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
  (NOT-DK-19-010)
  National Institute of Diabetes and Digestive and Kidney Diseases

- Notice of NIBIB's Participation in PAR-19-164 "Summer Research Education Experience Program (Clinical Trials Not Allowed R25)"
  (NOT-EB-19-001)
  National Institute of Biomedical Imaging and Bioengineering

- Notice of New Application Instructions for Classifying Training Program Area in PAR-17-341 "National Institute of General Medical Sciences Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32)"
  (NOT-GM-19-012)
  National Institute of General Medical Sciences

- Notice of Availability of Administrative Supplements for Equipment Purchases for NIGMS Awardees
  (NOT-GM-19-013)
  National Institute of General Medical Sciences

- Administrative Supplements to NIGMS Predoctoral Training Grants for Development of Curricular or Training Activities to Enhance Predoctoral Training
  (NOT-GM-19-015)
  National Institute of General Medical Sciences

- AHRQ Announces Change in Grant Recipient Purchasing of Identifiable CMS Data, effective FY2019
  (NOT-HS-19-007)
  Agency for Healthcare Research and Quality
- AHRQ Implementation of Final Rule on the Federal Policy for the Protection of Human Subjects (Common Rule)
  (NOT-HS-19-008)
  Agency for Healthcare Research and Quality

- Notice of NIMHD Participation in RFA-DA-19-034, "HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed)
  (NOT-MD-19-005)
  National Institute on Minority Health and Health Disparities

- Notice of NIMHD Participation in RFA-DA-19-035, "HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required)"
  (NOT-MD-19-006)
  National Institute on Minority Health and Health Disparities

- Notice of NIMHD's Interest in Research on Disability in Health Disparity Populations
  (NOT-MD-19-007)
  National Institute on Minority Health and Health Disparities

- Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PAR-19-070, Research on Current Topics in Alzheimer’s Disease and its Related Dementias (R01 Clinical Trial Optional)
  (NOT-MD-19-016)
  National Institute on Minority Health and Health Disparities

- Notice of Participation of the National Institute on Minority Health and Health Disparities (NIMHD) in PAR-19-071, Research on Current Topics in Alzheimer’s Disease and its Related Dementias (R21 Clinical Trial Not Allowed)
  (NOT-MD-19-017)
  National Institute on Minority Health and Health Disparities

- Notice of Intent to Publish a Funding Opportunity Announcement for Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (CWOW) (U54 Clinical Trial Optional)
  (NOT-NS-19-027)
  National Institute of Neurological Disorders and Stroke

- Notice of Letter of Intent Guidance for PAR-19-098 Emerging Global Leader Award (K43; Independent Clinical Trial Not Allowed) and PAR-19-051 Emerging Global Leader Award (K43; Independent Clinical Trial Required)
  (NOT-TW-19-001)
  John E. Fogarty International Center
  National Institute of Mental Health
Requests for Applications

- The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required)  
  *(RFA-CA-19-007)*  
  National Cancer Institute  
  Application Receipt Date(s): May 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed)  
  *(RFA-CA-19-008)*  
  National Cancer Institute  
  Application Receipt Date(s): May 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)  
  *(RFA-CA-19-019)*  
  National Cancer Institute  
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)  
  *(RFA-CA-19-020)*  
  National Cancer Institute  
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)  
  *(RFA-CA-19-021)*  
  National Cancer Institute  
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) (RFA-CA-19-022)
  National Cancer Institute
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) (RFA-CA-19-023)
  National Cancer Institute
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) (RFA-CA-19-024)
  National Cancer Institute
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) (RFA-CA-19-025)
  National Cancer Institute
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) (RFA-CA-19-026)
  National Cancer Institute
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- **Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)**
  
  (RFA-CA-19-027)
  
  National Cancer Institute
  
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)**
  
  (RFA-CA-19-028)
  
  National Cancer Institute
  
  Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)**
  
  (RFA-CA-19-033)
  
  National Cancer Institute
  
  Application Receipt Date(s): March 15, 2019; January 3, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional)**
  
  (RFA-DA-19-021)
  
  National Institute on Drug Abuse
  
  Application Receipt Date(s): March 19, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)**
  
  (RFA-DA-19-022)
  
  National Institute on Drug Abuse
  
  Application Receipt Date(s): March 19, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 - Clinical Trial Optional)**
  
  (RFA-DA-19-032)
  
  National Institute on Drug Abuse
  
  Application Receipt Date(s): March 20, 2019 by 5:00 PM local time of applicant organization.
- Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R43/R44 - Clinical Trial Optional)  
  (RFA-DA-19-033)  
  National Institute on Drug Abuse  
  Application Receipt Date(s): March 20, 2019, by 5:00 PM local time of applicant organization.

- Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)  
  (RFA-DK-18-008)  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt Date(s): March 21, 2019 by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)  
  (RFA-DK-18-509)  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  Application Receipt Date(s): March 21, 2019 by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- The Human Biomolecular Atlas Program (HuBMAP): Rapid Implementation of Technologies that Will Accelerate Development of a Framework for Mapping the Human Body at High Resolution (UH3 Clinical Trial Not Allowed)  
  (RFA-RM-19-002)  
  Office of Strategic Coordination (Common Fund)  
  Application Receipt Date(s): March 14, 2019, by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Program Announcements

- NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)  
  (PAR-19-145)  
  National Institute of Dental and Craniofacial Research  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 16, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed)  
  (PAR-19-146)  
  National Institute of Mental Health  
  National Institute on Aging  
  National Institute on Drug Abuse  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.  
  All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 16, 2019.
- Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)  
  (PAR-19-147)  
  National Institute of Mental Health  
  National Institute on Aging  
  National Institute on Drug Abuse  
  Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 5, 2019.

- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)  
  (PAR-19-149)  
  National Cancer Institute  
  National Institute of Arthritis and Musculoskeletal and Skin Diseases  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)  
  (PAR-19-150)  
  National Cancer Institute  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)  
  (PAR-19-151)  
  National Institute of Dental and Craniofacial Research  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed)  
  (PAR-19-152)  
  National Institute of Dental and Craniofacial Research  
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)  
(PAR-19-153)  
National Institute of Nursing Research  
National Cancer Institute  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 16, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)  
(PAR-19-155)  
National Heart, Lung, and Blood Institute  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 16, 2019.

• Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)  
(PAR-19-156)  
National Institute of Biomedical Imaging and Bioengineering  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Environmental Health Sciences  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Bioengineering Research Partnerships (U01 Clinical Trial Required)  
(PAR-19-157)  
National Institute of Biomedical Imaging and Bioengineering  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)  
(PAR-19-158)  
National Institute of Biomedical Imaging and Bioengineering  
National Cancer Institute  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Allergy and Infectious Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Neurological Disorders and Stroke
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Bioengineering Research Grants (BRG) (R01 Clinical Trial Required) (PAR-19-159)
  National Institute of Biomedical Imaging and Bioengineering
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed) (PAR-19-160)
  National Institute of Dental and Craniofacial Research
  Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required) (PAR-19-161)
  National Institute of Dental and Craniofacial Research
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed) (PAR-19-162)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Research on Women's Health
  Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
- **Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)**
  (PAR-19-163)
  National Institute on Drug Abuse
  National Cancer Institute
  *Eunice Kennedy Shriver* National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **Summer Research Education Experience Program (Clinical Trials Not Allowed R25)**
  (PAR-19-164)
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

******************************************************************************
You have received this information as a result of being subscribed to the UTHSCSA Office of Sponsored Programs fundinginfo2 ListServ. To remove yourself from this list, visit the Subscriber's Corner in the List Archives [http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2](http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2), and follow the onscreen instructions to log in and manage your list subscriptions.
******************************************************************************